RT Journal Article
SR Electronic
T1 Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e009262
DO 10.1136/jitc-2024-009262
VO 12
IS 7
A1 Yamamoto, Noboru
A1 Kitano, Shigehisa
A1 Koyama, Takafumi
A1 Ikeda, Masafumi
A1 Mizugaki, Hidenori
A1 Narikiyo, Takatsugu
A1 Yamaguchi, Yuki
A1 Ishida, Takaaki
A1 Takubo, Ryoko
A1 Ogami, Chika
A1 Sekiya, Mayuko
A1 Nakagawa, Yuki
A1 Kuboki, Yasutoshi
YR 2024
UL http://jitc.bmj.com/content/12/7/e009262.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.